109 related articles for article (PubMed ID: 11480537)
1. Designing multidrug-resistance modulators circumventing the reverse pH gradient in tumours.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2001 Jul; 53(7):1021-8. PubMed ID: 11480537
[TBL] [Abstract][Full Text] [Related]
2. Thermal dependence of multidrug-resistant-modulator efficiency: a study in anionic liposomes.
Castaing M; Loiseau A; Dani M
J Pharm Pharmacol; 2000 Oct; 52(10):1171-8. PubMed ID: 11092560
[TBL] [Abstract][Full Text] [Related]
3. Membrane permeation by multidrug-resistance-modulators and non-modulators: effects of hydrophobicity and electric charge.
Castaing M; Brouant P; Loiseau A; Santelli-Rouvier C; Santelli M; Alibert-Franco S; Mahamoud A; Barbe J
J Pharm Pharmacol; 2000 Mar; 52(3):289-96. PubMed ID: 10757416
[TBL] [Abstract][Full Text] [Related]
4. Interactions between verapamil and neutral and acidic liposomes: effects of the ionic strength.
Castaing M; Loiseau A; Mulliert G
Biochim Biophys Acta; 2003 Apr; 1611(1-2):107-14. PubMed ID: 12659951
[TBL] [Abstract][Full Text] [Related]
5. Effects of cholesterol on dye leakage induced by multidrug-resistance modulators from anionic liposomes.
Castaing M; Loiseau A; Djoudi L
Eur J Pharm Sci; 2003 Jan; 18(1):81-8. PubMed ID: 12554076
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance modulator interactions with neutral and anionic liposomes: membrane binding affinity and membrane perturbing activity.
Castaing M; Loiseau A; Mulliert G
J Pharm Pharmacol; 2005 May; 57(5):547-54. PubMed ID: 15901343
[TBL] [Abstract][Full Text] [Related]
7. Synergy between verapamil and other multidrug -resistance modulators in model membranes.
Castaing M; Loiseau A; Cornish-Bowden A
J Biosci; 2007 Jun; 32(4):737-46. PubMed ID: 17762146
[TBL] [Abstract][Full Text] [Related]
8. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery.
Webb MS; Wheeler JJ; Bally MB; Mayer LD
Biochim Biophys Acta; 1995 Sep; 1238(2):147-55. PubMed ID: 7548129
[TBL] [Abstract][Full Text] [Related]
9. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
10. Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?
Hoffman MM; Wei LY; Roepe PD
J Gen Physiol; 1996 Oct; 108(4):295-313. PubMed ID: 8894978
[TBL] [Abstract][Full Text] [Related]
11. Free fatty acids cause pH-dependent changes in drug-lipid membrane interactions around physiological pH.
Krämer SD; Jakits-Deiser C; Wunderli-Allenspach H
Pharm Res; 1997 Jun; 14(6):827-32. PubMed ID: 9210205
[TBL] [Abstract][Full Text] [Related]
12. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein.
Roepe PD; Wei LY; Cruz J; Carlson D
Biochemistry; 1993 Oct; 32(41):11042-56. PubMed ID: 8105888
[TBL] [Abstract][Full Text] [Related]
13. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
14. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.
Drori S; Eytan GD; Assaraf YG
Eur J Biochem; 1995 Mar; 228(3):1020-9. PubMed ID: 7737146
[TBL] [Abstract][Full Text] [Related]
16. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
Lee RJ; Wang S; Turk MJ; Low PS
Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
18. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
19. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines.
Martínez-Zaguilán R; Raghunand N; Lynch RM; Bellamy W; Martinez GM; Rojas B; Smith D; Dalton WS; Gillies RJ
Biochem Pharmacol; 1999 May; 57(9):1037-46. PubMed ID: 10796074
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of weak electrolytes after the adaptation of cells to low pH: role of the transmembrane pH gradient.
Kozin SV; Gerweck LE
Br J Cancer; 1998 May; 77(10):1580-5. PubMed ID: 9635832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
